Was everyone wrong about fish oil? Is venture capital a cartel? And what’s with all those ketamine clinics?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a recap of the news that shocked biotech: A prescription-grade fish oil significantly reduced the risks of heart attacks and strokes. Then we talk to STAT’s Megan Thielking about her investigation into the rapid rise — and considerable risks — of clinics offering ketamine as an off-label treatment for depression. And biotech entrepreneur Ethan Perlstein joins us to talk about the flaws he sees in biotech’s venture capital model. Finally, there’s a lightning round, exploring identical migraine drugs, impoverished pharma CEOs, and why hedge fund managers can’t get enough of drug stocks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy